Comparison of GnRH agonist versus luteal estradiol GnRH antagonist protocol using transdermal testosterone in poor responders

JBRA Assist Reprod. 2019 Apr 30;23(2):130-136. doi: 10.5935/1518-0557.20180090.

Abstract

Objective: Transdermal testosterone has been used in different doses and in different stimulation protocols in poor responders. The aim of the present study is to compare the luteal estradiol/GnRH antagonists protocol versus long GnRH agonists in poor responder patients according to the Bologna criteria, in which transdermal testosterone has been used prior to the stimulation with gonadotropins.

Methods: In this retrospective analysis, a total of 141 poor responder patients according to the Bologna criteria were recruited. All patients were treated with transdermal testosterone preceding ovarian stimulation with gonadotropins during 5 days. In 53 patients we used the conventional antagonist protocol (Group 1). In 88 patients (GrH pituitary suppression was achieved by leuprolide acetate according to the conventional long protocol (Group 2). We analyzed the ovarian stimulation parameters and IVF outcomes.

Results: Comparing groups 1 and 2, there were no significant differences between cancellation rates and number of oocytes retrieved. However the total gonadotropin dose used and the mean length of stimulation were significantly lower in group 1 when compared to group 2. There were no significant differences in pregnancy outcomes; however, there was a slight increase in the implantation rate in group 1 vis-a-vis group 2, although statistical significance was not achieved.

Conclusion: TT in poor responder patients can be effective both with the conventional agonist's long protocol and with the conventional antagonist's protocol. However, short regimes with previous estradiol antagonists in the luteal phase facilitate ovarian stimulation by shortening the days of treatment and the consumption of gonadotropins.

Keywords: Bologna criteria; GnRH analogues; estradiol priming; ovarian stimulation; poor responder; transdermal testosterone.

MeSH terms

  • Administration, Cutaneous
  • Adult
  • Estradiol* / administration & dosage
  • Estradiol* / therapeutic use
  • Female
  • Gonadotropin-Releasing Hormone* / agonists
  • Gonadotropin-Releasing Hormone* / antagonists & inhibitors
  • Hormones* / administration & dosage
  • Hormones* / therapeutic use
  • Humans
  • Luteal Phase
  • Ovulation Induction* / methods
  • Ovulation Induction* / statistics & numerical data
  • Pregnancy / statistics & numerical data
  • Retrospective Studies
  • Testosterone* / administration & dosage
  • Testosterone* / therapeutic use

Substances

  • Hormones
  • Gonadotropin-Releasing Hormone
  • Testosterone
  • Estradiol